You are here

Novel Transcription Profiling in Toxicologic Assays

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41ES013799-01
Agency Tracking Number: ES013799
Amount: $224,568.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2005
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
5310 Eastgate Mall
San Diego, CA 92121
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARY WARREN
 (858) 792-7932
Business Contact
Phone: (858) 457-3250
Research Institution
 UNIVERSITY OF PITTSBURGH
 
UNIVERSITY OF PITTSBURGH 4200 5TH AVE
PITTSBURGH, PA 15260
United States

 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant): A common reason for failure of drugs in development or their removal from the market is hepatotoxicity. This is due to the many adverse drug reactions and drug-drug interactions that result from drug metabolism, enzyme induction or inhibition of drug metabolizing enzymes. Unfortunately, effective in vitro and in vivo approaches to accurately predict hepatotoxicity of new chemical entities in humans are lacking. Numerous reports have shown recently that changes in gene activity can provide highly valuable information about toxicological endpoints. Within that area, RNA profiling has typically been the standard for identifying differential gene expression. However, these methods also have limitations. A new and novel platform technology, called TranscriptionPath and based on chromatin immunoprecipitation of DNA-transcription machinery complexes, identifies genes undergoing active transcription inside cells and quantifies very accurately and reproducibly their levels of transcription. Further, TranscriptionPath is powerful in being able to measure very early transcriptional changes inside cells and tissues, which should permit the identification of changes at the beginnings of metabolic pathways. This proposal will apply the new TranscriptionPath method to the identification of gene transcription changes in liver at early time points after treatment of rats with drugs known to result in chemically-induced hepatotoxicity. In addition, the same drugs will be used to treat isolated rat hepatocytes, which will also be transcriptionally profiled to determine if the same gene expression changes are observed in vitro. Gene transcription changes will also be correlated with functional biochemical changes. In Phase II, the diagnostic profiles derived from the rat studies will be used to assess the cross-species scaling of the hepatotoxic endpoints and to identify new gene expression signatures predictive of hepatotoxic potential in humans. Development of the technology proposed herein should significantly help improve preclinical safety assessment and eventually help companies, governmental agencies and academic entities develop safer drugs in less time and with lower costs.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government